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   What  ’  s known on the subject? and What does the study add?    
  Largest survey ever conducted evaluating the management of AUR in real life practice 
in a wide range of health care systems. It shows that urethral catheterization followed 
by a TWOC has become a standard worldwide and that   α  1  -blockade prior to TWOC 
doubles the chances of success. It also evidences important differences (hospitalization 
rate, duration of catheterization   . . .  ) between countries/regions reﬂ  ecting lack of 
guidelines. This large survey also clearly identiﬁ  es predictors of TWOC failure. 
  OBJECTIVES 
     ￿      To  evaluate  the  management  of  acute 
urinary retention (AUR) associated with 
benign prostatic hyperplasia (BPH) in 
real-life practice.   
    ￿      To  identify  predictors  of  successful  trial 
without catheter (TWOC).     
  MATERIALS AND METHODS 
     ￿      In  all,  6074  men  catheterized  for  painful 
AUR were enrolled in a prospective, 
cross-sectional survey conducted in public 
and private urology practices in France, 
Asia, Latin America, Algeria and the Middle 
East.  
    ￿      Patient  clinical  characteristics,  type  of 
AUR and its management (type of 
catheterization, hospitalization, TWOC, use 
of   α  1  -blockers, immediate or elective 
surgery) and adverse events observed 
during the catheterization period were 
recorded.  
    ￿      Predictors  of  TWOC  success  were  also 
analysed by multivariate regression analysis 
with stepwise procedure.     
  RESULTS 
     ￿      Of  the  6074  men,  4289  (71%)  had  a 
spontaneous AUR and 1785 (29%) had a 
precipitated AUR, mainly as the result of 
loco-regional/general anaesthesia (28.5%) 
and excessive alcohol intake (18.2%).   
    ￿      Presence  of  BPH  was  revealed  by  AUR  in 
44% of men. Hospitalization for AUR 
varied between countries, ranging from 
1.7% in Algeria to 100% in France. A 
urethral catheter was inserted in most 
cases (89.8%) usually followed by a TWOC 
(78.0%) after a median of 5 days. Overall 
TWOC success rate was 61%.   
    ￿      Most  men  (86%)  received  an   α  1 -blocker 
(mainly alfuzosin) before catheter removal 
with consistently higher TWOC success 
rates, regardless of age and type of AUR. 
Multivariate regression analysis conﬁ  rmed 
that   α  1  -blocker before TWOC doubled the 
chances of success (odds ratio 1.92, 95% CI 
1.52 – 2.42,   P      <     0.001  ).  
    ￿      Age   ≥  70 years, prostate size   ≥ 50    g, 
severe lower urinary tract symptoms, 
drained volume at catheterization 
  ≥  1000     mL and spontaneous AUR favoured 
TWOC failure. Catheterization   >  3 days did 
not inﬂ  uence TWOC success but was 
associated with increased morbidity and 
prolonged hospitalization for adverse 
events.  
    ￿      In  the  case  of  TWOC  failure,  49%  of  men 
were recatheterized and had BPH surgery 
and 43.5% tried another TWOC with a 
success rate of 29.5%. Elective surgery was 
preferred to immediate surgery.     
  CONCLUSIONS 
     ￿      TWOC  has  become  a  standard  practice 
worldwide for men with BPH and AUR.   
    ￿      In  most  cases,  an   α  1 -blocker  is 
prescribed before TWOC and signiﬁ  cantly 
increases the chance of success.   
    ￿      Prolonged  catheterization  is  associated 
with  an  increased  morbidity.    
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      INTRODUCTION 
  Acute urinary retention (AUR) is a severe 
complication of BPH characterized by a 
sudden and painful inability to void 
voluntarily    [ 1 ]  .  It  is  a  distressing  condition 
  [ 2 ]    that  represents  a  major  public  health 
issue. Within the last decade, AUR has 
become the most common indication for 
TURP, increasing from 22.9% in 1988 to 
42.9%  in  1998    [ 3 ]  .  In  addition,  a  recent 
analysis of 176     046 men admitted to NHS 
hospitals in England for AUR between 1998 
and 2005 has shown that mortality within 
the year after a ﬁ  rst AUR episode was much 
higher than in the general population, 
especially  in  younger  patients    [ 4 ]  . 
  In clinical practice, AUR is usually attributed 
to BPH, as being part of its natural history 
(so-called   ‘ spontaneous  AUR ’ ).  Data  from 
large community-based longitudinal studies 
have identiﬁ  ed old age, severe lower urinary 
tract symptoms (LUTS), low peak ﬂ  ow rate, 
high postvoid residual urine (PVR), enlarged 
prostate and high serum PSA as signiﬁ  cant 
risk  factors  for  spontaneous  AUR    [ 5,6 ]  . 
Dynamic variables such as symptom 
worsening and increasing PVR during 
medical therapy are also powerful predictors 
of AUR     [  7,8  ]    . In other cases, AUR develops 
after a precipitating event other than BPH 
(so-called   ‘  precipitated  ’   AUR), for example a 
surgical procedure with general or loco-
regional anaesthesia, bladder overdistension, 
urinary tract infection, medications with 
sympathomimetic or anticholinergic effects 
  [ 9 ]  .  The  differentiation  between  both  types 
of AUR is relevant in clinical practice 
because precipitated AUR is associated with 
a much higher mortality rate at 1 year 
(24-fold increase vs general population) 
than spontaneous AUR (10-fold increase) 
    [  4  ]    . This is possibly explained by a higher 
prevalence of severe underlying comorbid 
conditions in men with precipitated AUR 
and this may have important implications in 
terms of AUR management. 
  Management of AUR consists of immediate 
bladder decompression by catheterization 
usually followed by BPH-related surgery. 
The evidence that emergency surgery was 
associated with an increased mortality 
rate at 30 days and a higher rate of 
postoperative complications, and the 
potential morbidity associated with 
prolonged catheterization have led to an 
increasing use of a trial without catheter 
(TWOC)    [ 9,10 ]  .  A  TWOC  involves  catheter 
removal, usually after 2  –  3 days of   α  1 -
blockade, allowing the patient to return to 
normal voiding in up to 60% of cases 
  [ 10,11 ]  .  The  beneﬁ  t of   α  1  -blockade on the 
TWOC success rate was shown in a large 
double-blind, placebo-controlled study that 
randomized 360 men with AUR to alfuzosin 
10     mg once daily or placebo for 2  –  3 days 
followed  by  a  TWOC    [ 11 ]  .  It  was  further 
established by a recent Cochrane 
metaanalysis    [ 12 ]  .  This  TWOC  policy  is  likely 
to have contributed to the decrease in the 
number of TURPs after a ﬁ  rst AUR episode 
in the UK but balanced against this is a 
slight increase in the AUR recurrence rate 
  [ 13 ]  . 
  Nevertheless, there is currently no consensus 
on the optimal management of AUR, in 
terms of type of catheterization, duration of 
catheterization and management after 
catheterization. The Reten-World survey 
aimed to evaluate prospectively the current 
practice in management of AUR associated 
with BPH, in various regions (France, Latin 
America, Asia, Algeria, Middle East) 
representing a wide range of healthcare 
systems.  
    METHODS 
  In all, 6074 men presenting with a painful 
AUR related to BPH were enrolled between 
April 2004 and April 2008 by 953 urologists 
from public (37%), private (42%) or mixed 
(21%) healthcare practices in a prospective 
cross-sectional survey conducted in France 
(  n      =       2618), Asia (Korea, Pakistan, Philippines, 
Taiwan, Thailand, Vietnam;   n      =     1727),  Latin 
America (Colombia, Mexico, Venezuela; 
  n      =     883),  Algeria  ( n      =       755) and the Middle 
East (Bahrain, Qatar, Kuwait, United Arab 
Emirates;   n      =       91). The results of the French 
survey  have  already  been  published    [ 14 ]  . 
Patient demographic data, history of BPH, 
prostate size estimated by DRE, type of AUR 
(spontaneous or precipitated), amount of 
drained volume, management of AUR (type 
and duration of catheterization, TWOC, use 
of   α  1  -blockers before TWOC, hospitalization 
rate, immediate or elective surgery) and 
adverse events observed during the 
catheterization period were recorded. 
Written informed consent was obtained 
from all patients. Study protocol was 
approved by the ethics committees and 
Health Authorities, according to local 
legislation. 
  Statistical comparisons were made using 
chi-squared or Fisher exact test for 
qualitative variables and Student  ’  s   t   test for 
quantitative variables. A   P   value   <     0.05 
was considered statistically signiﬁ  cant. A 
multiple logistic regression analysis with 
stepwise procedure was performed to 
determine whether the TWOC success rate 
was inﬂ  uenced by selected variables (age 
  <  70 or   ≥  70 years, LUTS severity according 
to International Prostate Symptom Score, 
prostate size   ≤  50 or   > 50    mL,  catheterization 
for   ≤  3 or   >  3 days, drained volume at 
catheterization   <  1000 or   ≥ 1000    mL, 
  α  1  -blockade before TWOC). The calculations 
were performed using the Statistical 
Analysis System (version 9.1.3; SAS Institute 
Inc. Cary, NC, USA).   
    RESULTS 
  Of the 6074 men enrolled, 4289 (70.6%) 
had a spontaneous AUR and 1785 (29.4%) 
had a precipitated AUR. Patient clinical 
characteristics are provided globally and by 
region  in   Table    1   .  Algeria  showed  the  lowest 
rate of precipitated AUR (11.9%) whereas 
Latin America showed the highest rate 
(43.8%), mainly consecutive to excessive 
alcohol intake (  Fig.     1  ). Another important 
triggering event for AUR was surgery with 
loco-regional/general anaesthesia, especially 
in France. A previous AUR episode was 
reported by 16.5% of men, ranging from 
10% in France to 24% in the Middle East, 
within a median delay of 7 months before 
enrolment. Compared with spontaneous 
AURs, precipitated AURs were characterized 
by signiﬁ  cantly less severe LUTS (22.3% vs 
31.7%,   P      <       0.001), a lower percentage of 
prostate glands   >  50     g (36.9% vs 45.4%, 
  P      <       0.001) and a higher rate of BPH revealed 
by AUR (44.2% vs 32.9%,   P      <     0.001). 
  Catheterization was performed almost 
exclusively by urologists in France (81.3%) 
but it was performed by an emergency room 
physician in up to 40.9% of patients in 
other regions (  Table     2  ). A urethral catheter 
was inserted in most cases (89.8%), 
whatever the region. France showed the 
highest rate of suprapubic catheter insertion 
(16.7%). The hospitalization rate for AUR 
varied between regions, ranging from 1.7% 
in Algeria to 100% in France. 
  After initial catheterization, TWOC was the 
standard whatever the region (76.8%) FITZPATRICK ET AL.
  ©  2011 THE AUTHORS
90  BJU INTERNATIONAL ©  2011 BJU INTERNATIONAL
    TABLE    1    Clinical characteristics of 6074 men catheterized for painful acute urinary retention     
Total
  (  N      =     6074)
France
  (  N      =     2618)
Asia
  (  N      =     1727)
Latin America
  (  N      =     883)
Algeria
  (  N      =     755)
Middle East
  (  N      =     9 1 )
Age, years
    Median 70 72 70 68 72 65
     < 65,  % 27.4 26.0 26.2 37.0 20.5 49.4
    65 – 74,  % 39.3 37.6 41.6 37.6 42.1 38.5
     ≥ 75,  % 33.3 36.4 32.2 25.4 37.4 12.1
Type of AUR, %
    Spontaneous 70.6 71.6 68.8 56.2 88.1 71.4
    Precipitated 29.4 28.4 31.2 43.8 11.9 28.6
BPH revealed by AUR, %
    Yes 36.2 33.2 37.6 39.5 40.1 30.8
    No 63.8 66.8 62.4 60.5 59.9 69.2
Severity  of  LUTS  *  ,  %
    Mild 13.3 16.8 7.6 14.8 13.6 14.3
    Moderate 57.5 61.3 51.8 57.2 56.9 75.0
    Severe 29.2 21.9 40.6 27.9 29.6 10.7
DRE  estimated  prostate  size  †  ,  g
     < 30,  % 6.5 6.1 11.3 3.7 0.3 3.3
    30 – 50,  % 50.4 44.6 60.3 50.2 43.3 36.3
     > 50,  % 43.1 49.3 28.4 46.1 56.4 60.4
History of previous AUR
    Yes,  % 16.5 10.2 23.6 19.6 18.0 24.2
    Median  delay,  months 6.9 7.2 7.5 7.9 4.5 8.4
            *    Available in 3874 men. Lower urinary tract symptom severity evaluated according to International Prostate Symptom Score.      †  Available  in  5013  men.  AUR, 
acute urinary retention; BPH, benign prostatic hyperplasia; DRE, digital rectal examination; LUTS, lower urinary tract symptoms.       
         FIG.    1.   
Triggering event in 
1785 men catheterized 
for a precipitated acute 
urinary retention. UTI, 
urinary  tract  infection.   
Acute
anorectal pain
Need to postpone
voiding
Faecal impaction
Medication
Important
alcohol intake
UTI
Postoperative
France
Asia
Latin America
Algeria
Middle-East
0              10            20             30            40             50
(  Table     2  ), with slightly higher rates for 
precipitated AURs compared with 
spontaneous AURs (86.1% vs 73% 
respectively,   P      <       0.001). Overall, 13.3% of 
men were managed by prolonged 
catheterization followed by programmed 
surgery, the highest rates being reported in 
France (17.9%) and Latin America (15.1%). 
Immediate surgery was less common (7.2%), 
the highest rate being reported in Asia 
(12.9%) and the lowest in Algeria (0.5%). 
Compared with precipitated AURs, 
spontaneous AURs were more likely to be 
treated by surgery, either immediately (8.4% 
vs 4.3%,   P      <       0.001) or after prolonged 
catheterization (15.6% vs 7.6%,   P      <     0.001). 
  In all, 4667 men underwent a ﬁ  rst TWOC 
with an overall success rate of 61.4% 
(precipitated AUR 66.3%, spontaneous AUR 
59.0%,   P      <       0.001). Median duration of 
catheterization before TWOC ranged from 3 
days in France to 8 days in Algeria. Most 
men (85.9%) received an   α  1 -blocker  before 
the TWOC (alfuzosin 68.2%, tamsulosin 
16.5%, doxazosin 6.1%, terazosin 2.6%, 
prazosin 0.1%). Use of an   α  1 -blocker  before 
TWOC signiﬁ  cantly increased overall the 
success rate (63.4% vs 49.5%,   P      <     0.001), 
including for spontaneous (61.4% vs 44.5%, 
  P      <       0.001) and precipitated (67.5% vs 
59.0%,   P      =       0.01) AURs. Similarly, the beneﬁ  t 
of   α  1  -blockade before TWOC was conﬁ  rmed 
irrespective  of  age  ( Fig.    2 ). 
  Univariate regression analysis showed that 
older age (  ≥  70 years), enlarged prostates 
(  >  50     g), severe LUTS, large drained volume 
at catheterization (  ≥  1000     mL) and AUR of 
spontaneous origin were associated with 
signiﬁ  cantly higher rates of TWOC failure 
whereas catheterization for   >  3 days and 
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rates  ( Fig.    3   ).  Multivariate  analysis  with 
a stepwise procedure conﬁ  rmed the 
predictive value of these variables on 
TWOC outcome except for catheterization 
duration   >  3 days, which was no more 
    TABLE    2    Initial management of acute urinary retention (AUR) in 6074 men catheterized for painful AUR     
Total
  (  N      =     6074)
France
  (  N      =     2618)
Asia
  (  N      =     1727)
Latin America
  (  N      =     883)
Algeria
  (  N      =     755)
Middle East
  (  N      =     9 1 )
Type of practice, %
    Public 37.4 33.1 85.7 16.9 83.3 40.0
    Private 41.9 54.9 1.0 22.3 16.7 10.0
    Both 20.7 12.0 13.3 60.8 0 50.0
Type of catheter, %
    Urethral 89.8 82.7 94.5 98.1 93.1 95.6
    Suprapubic 8.2 16.7 1.8 1.0 2.3 3.3
    In  and  out 1.8 0 3.7 0.9 4.6 1.1
    Unspeciﬁ  ed 0.3 0.6 0 0 0 0
Catheterization performed by, %
    Urologist 60.5 81.3 36.5 59.0 50.1 63.7
    Emergency  room  physician 21.1 0.4 35.8 30.6 40.9 33.0
    Nurse 15.3 17.3 21.5 8.4 4.4 1.1
    Other 3.2 1.0 6.1 2.0 4.6 2.2
Drained volume, %
     < 1000    mL 68.4 63.2 72.6 67.7 77.0 75.8
     ≥ 1000    mL 31.6 36.8 27.4 32.3 23.0 24.2
Hospitalization for AUR
    Yes,  % 57.4 100.0 40.4 12.6 1.7 52.7
Management after catheterization
    TWOC 76.8 72.8 75.4 75.8 93.6 91.2
    Immediate  surgery 7.2 5.7 12.9 6.5 0.5 4.4
      Prolonged catheter and elective 
surgery
13.3 17.9 9.4 15.1 5.0 4.4
    Stent 0.2 0.4 0.1 0 0 0
    Indwelling  catheter 1.6 1.1 2.4 2.6 0.5 0
    Unspeciﬁ  ed 1.1 2.1 0 0.2 0.3 0
   TWOC,  trial  without  catheter.      
         FIG.    2.  
Impact of   α  1 -blockade 
on trial without 
catheter (TWOC) 
success rate by age.     
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signiﬁ  cant. Allowing for all these factors, 
  α  1  -blocker before a TWOC still doubled 
the chances of successful TWOC (odds 
ratio 1.92, 95% CI 1.52  –  2.42,   P      <     0.001) 
( Table    3 )  . 
  Of the 2862 men with successful ﬁ  rst TWOC, 
most (86.7%) continued on   α  1 -blockade 
(alone 76.1% or combined either with a 
5  α  -reductase inhibitor, 8.4%, or a plant 
extract, 2.2%) while being followed up 
regularly (  Table     4  ). In all, 5.7% had 
programmed surgery whatever the outcome 
(spontaneous AUR 6.0%, precipitated AUR 
5.2%,   P      =       ns) whereas 19.7% would have 
surgery performed if needed (precipitated 
AUR 13.0%, spontaneous AUR 23.3%, 
  P      <     0.001). 
  Of the 1798 men who failed a ﬁ  rst TWOC, 
most (49%) were recatheterized and 
underwent BPH-related surgery whereas 
43.5% tried another TWOC after a median of 
8 days after the catheterization    . The second 
TWOC was successful in 29.5% of cases 
(precipitated AUR 34.0%, spontaneous AUR 
27.5%,   P      =       0.07), ranging from 19.7% in 
Algeria  to  44.1%  in  Asia  ( Table    4 ;   Fig.    4 ).  Of FITZPATRICK ET AL.
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Odds ratio (95% CI)   P   value
Age (median)
     < 70  years 1   < 0.001
     ≥ 70  years 0.73 (0.62  –  0.86)
Type of AUR
    Precipitated 1   < 0.001
    Spontaneous 0.70  (0.58 – 0.70)
Amount of drained volume
     < 1000    mL 1   < 0.001
     ≥ 1000    mL 0.62  (0.51 – 0.74)
  α  1  -blocker before TWOC
    No 1   < 0.001
    Yes 1.92  (1.52 – 2.42)
LUTS severity before AUR
    Mild 1 0.51
   < 0.001     Moderate 0.93  (0.73 – 1.17)
    Severe 0.61  (0.47 – 0.80)
Prostate volume
     ≤ 50    g 1   < 0.001
     > 50    g 0.63 (0.53  –  0.74)
    TABLE    3   
Predictors of trial without 
catheter success rate 
(multiple logistic regression 
analysis)     
   AUR,  acute  urinary 
retention; 95% CI, 95% 
conﬁ  dence interval; LUTS, 
lower tract urinary 
symptoms; TWOC, trial 
without  catheter.      
         FIG.    3.   Signiﬁ  cant predictors of trial without catheter (TWOC) success in univariate analysis. P, precipitated 
acute urinary retention (AUR); S, spontaneous AUR; IPSS, International Prostate Symptom Score; catheter 
duration is expressed in days.     
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the 542 men who failed a second TWOC, 
70.7% were recatheterized and had surgery, 
18.8% tried a third TWOC with an overall 
success rate of 26.4% and 10.5% had 
another approach. 
  Catheterization for more than 3 days was 
associated with a signiﬁ  cantly higher rate 
of adverse events compared with those 
catheterized for 3 days or less (33.8% vs 
19.7%,   P      <     0.001)  ( Table    5 ).  In  patients  who 
were hospitalized, prolonged catheterization 
also resulted in a slightly higher rate of 
prolonged hospitalization for adverse events 
(5.2% vs 3.5%,   P      =     0.007).  
    DISCUSSION 
  Acute urinary retention represents the 
commonest indication for BPH-related 
surgery    [ 3 ]    but  its  management  is  still  not 
standardized because of a lack of existing 
guidelines. The cross-sectional survey 
described here evaluates prospectively the 
management of AUR in a wide range of 
healthcare systems. The key ﬁ  ndings may 
be summarized as follows. First, initial 
management of AUR mainly consists of 
urethral catheterization followed by TWOC 
but important differences exist between 
countries regarding hospitalization rate, 
duration of catheterization and management 
of TWOC outcome. Second, it conﬁ  rms in 
real-life practice that older age, severe LUTS, 
large drained volume at catheterization and 
AUR of spontaneous origin favour TWOC 
failure. Nevertheless, considering all these 
factors,   α  1  -blockade before a TWOC still 
doubles the chances of success. Third, 
prolonged catheterization (  >  3 days) does 
not inﬂ  uence TWOC outcome in multivariate 
analysis but is associated with a greater 
comorbidity and a prolonged hospitalization 
rate because of adverse events. Fourth, 
if the ﬁ  rst TWOC fails, another TWOC 
may be attempted with a success rate of 
29.5%. Last, only a few men (one in four) 
undergoes BPH-related surgery after a ﬁ  rst 
episode of AUR, elective surgery being 
preferred to immediate surgery. 
  Before discussing the policy implications of 
the survey, some methodological aspects 
should be considered. There was no random 
selection of participating centres, which 
raises the question if they were fully 
representative of standard of care in a 
given country. Our survey is the largest 
ever conducted in this setting and was 
speciﬁ  cally designed to include at least 50% 
of urology centres in each country, both in 
public and private practice. In our opinion, it 
provides the physician with reliable and 
useful information on AUR management in 
a given country. It also allows comparison of 
daily practices to a wide range of healthcare 
systems, showing not only common trends 
between countries but also important 
differences, which need to be addressed to 
optimize patient care. 
  In this survey, the hospitalization rate for 
AUR varied between countries, ranging 
from 1.7% in Algeria to 100% in France. 
This obviously reﬂ  ects major differences 
between healthcare systems but it also 
questions the necessity of hospitalizing men 
presenting with AUR. In a UK survey, 65.5% 
of physicians automatically admitted men 
catheterized for AUR whereas 19.3% would 
only  admit  those  with  renal  impairment    [ 10 ]  . 
According to the UK National Prostatectomy 
Audit, men discharged home after MANAGEMENT OF ACUTE URINARY RETENTION ASSOCIATED WITH BPH
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    TABLE    4    Management in case of TWOC     
Total
  (  N      =     4667)
France
  (  N      =     1906)
Asia
  (  N      =     1302)
Latin America
  (  N      =     669)
Algeria
  (  N      =     7 07 )
Middle East
  (  N      =     8 3 )
Duration of catheterization before a ﬁ  rst TWOC, days
    Median 5 3 6 6 8 7
     ≤  3 days, % 41.3 65.2 30.8 24.6 19.5 20.7
     >  3 days, % 58.7 34.8 69.2 75.4 80.5 79.3
  α  1 -blockade  before  TWOC  *  
    Yes,  % 85.9 79.0 89.5 85.1 97.7 92.8
First TWOC (  n )
    Success  rate,  % 61.4 50.2 66.0 75.2 69.0 71.1
Outcome if ﬁ  rst TWOC is a success    †   
    Medical  treatment,  % 88.8 76.8 94.8 89.3 99.6 98.3
      Surgery whatever the outcome, % 5.7 8.5 3.1 9.3 1.4 1.7
      Surveillance and surgery if needed, % 19.7 24.8 4.5 5.0 53.1 5.1
    Other,  % 3.4 0.4 0.7 0 0 0
Outcome if ﬁ  rst TWOC fails
      Recatheterize and try a second TWOC 43.5 33.4 42.8 45.8 85.8 54.2
      Recatheterize and plan surgery 49.0 57.5 48.9 51.2 12.8 33.3
    Stent 0.9 1.5 0 0 0 12.5
    Long-term  catheter 2.8 1.1 7.2 3.0 1.8 0
    Other 3.5 6.1 1.1 0 0 0
Second TWOC (  n ) (782) (316) (189) (76) (188) (13)
    Success  rate,  % 29.5 25.9 44.1 30.7 19.7 38.5
Outcome if second TWOC is a success    †   
    Medical  treatment,  % 88.8 77.2 97.6 82.6 100 100
      Surgery whatever the outcome, % 5.7 7.6 3.1 9.3 1.4 1.7
      Surveillance and surgery if needed, % 19.7 24.8 4.5 5.0 53.1 5.1
    Other,  % 3.4 0.4 0.7 0 0 0
Outcome if second TWOC fails
      Recatheterize and try a third TWOC 18.8 6.2 39.0 26.9 21.2 12.5
      Recatheterize and plan surgery 70.7 77.0 51.4 67.3 74.8 87.5
    Stent 1.7 4.0 0 0 0 0
    Long-term  catheter 7.0 8.0 10.5 5.8 4.0 0
    Other 3.3 6.2 2.9 1.9 0 0
Third TWOC (  n ) (102) (14) (41) (14) (32) (1)
    Success  rate,  % 26.4 NR 32.5 21.4 18.8 100
            *    Alfuzosin 68.2%, tamsulosin 16.5%, doxazosin 6.1%, terazosin 2.6%, prazosin 0.1%.         †    Sum is higher than 100% because several options may be ticked.NR, 
not  reported,  TWOC,  trial  without  catheter.       
         FIG.    4.  
Trial without catheter 
(TWOC) success rate by 
type of acute urinary 
retention (AUR) after 
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catheterization to await surgery showed a 
higher rate of uncomplicated urinary tract 
infection and consequently received more 
antibiotics than those kept in hospital 
but there was no increased risk of major 
infective  complications    [ 15,16 ]  .  Nevertheless, 
cost savings of sending the patient home 
should be balanced against patient 
discomfort and anxiety generated by the 
catheter being   in situ   outside the hospital. 
  The survey also establishes TWOC as 
standard practice worldwide (76.8%) in FITZPATRICK ET AL.
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    TABLE    5    Impact of catheter duration of the adverse event proﬁ   le   
  ≤ 3  days 
(  n      =     1853), 
  n   (%)
  > 3  days 
(  n      =     2638), 
  n   (%)  P   value
At least one adverse event during catheter period 281 (19.7) 1453 (33.8)   < 0.001
Haematuria 177 (9.6) 274 (10.4) 0.35
Asymptomatic bacteriuria 81 (5.7) 579 (13.5)   < 0.001
Lower urinary tract infection 49 (3.4) 308 (7.2)   < 0.001
Urosepsis 9 (0.6) 51 (1.2) 0.06
Urine leak 52 (3.7) 297 (6.9)   < 0.001
Catheter obstruction 12 (0.8) 133 (3.1)   < 0.001
Other adverse events 14 (1.0) 72 (1.7) 0.05
Prolongation of hospitalization for adverse event 47 (3.5) 209 (5.2) 0.007
men catheterized for AUR, with an overall 
success rate of 61%. The advantage of 
TWOC is that it allows BPH-related surgery 
to be performed later, and without the 
morbidity associated with a catheter. 
According to the UK National Prostatectomy 
Audit, deferred surgery for AUR is associated 
with signiﬁ  cantly reduced risks of 
perioperative complications and 
postoperative  death  at  30  days    [ 15 ]  .  This 
 ‘ window  of  opportunity ’   possibly  allows 
patients, who are usually elderly with 
comorbid conditions, to face surgery in 
 ‘ ﬁ  tter condition  ’   with a better detrusor 
function. Our results are in agreement 
with those of a UK survey conducted 
among  410  consultant  urologists    [ 10 ]   
showing that most of them (73.9%) were 
using TWOC, mainly after 2 days 
catheterization (48.5%). 
  The large database collected here (4667 men 
with TWOC), allowed us to conduct a robust 
analysis of predictors of TWOC outcome. 
Multivariate analysis identiﬁ  ed older age 
(  ≥  70 years), large prostates (  ≥ 50    g), 
severe LUTS, large drained volume at 
catheterization (  ≥  1000     mL) and AUR of 
spontaneous type as predictors of TWOC 
failure. Nevertheless, even in the presence of 
these adverse factors,   α  1 -blockade  before 
TWOC almost doubled the chances of 
success. This is in agreement with the 
ALFAUR (Alfuzosin in Acute Urinary 
Retention) study, which also reported a 
higher rate of failed TWOC in men age   ≥ 65 
years or with a drained volume   ≥ 1000    mL 
and a twice as high chance of success in 
men treated with alfuzosin within the 2  –  3 
days  before  TWOC    [ 11 ]  .  The  beneﬁ  t of 
  α  1  -blockade before TWOC was further 
established by a Cochrane metaanalysis of 
ﬁ  ve randomized trials, including four with 
alfuzosin    [ 12 ]  .  It  conﬁ  rms an old concept, 
which was initially suggested by Caine   et   al . 
in 1976     [  17  ]    , that AUR is the consequence 
of a sudden sympathetic stimulation causing 
an acute increase in smooth muscle tone in 
the lower urinary tract. By relaxing the 
smooth muscle tone,   α  1 -blockers  would 
then favour a return to normal voiding. 
  It has been reported that chances of 
successful TWOC increase with the 
duration  of  catheterization    [ 18 ]  .  Our 
survey also showed in a univariate 
analysis that catheterization for   > 3  days 
was associated with higher TWOC success 
rates. Nevertheless, in multivariate analysis, 
duration of catheterization before TWOC 
was no more signiﬁ  cant. In our opinion, 
considering the fact that longer catheter 
duration signiﬁ  cantly increases the risk 
of complications such as urinary tract 
infections, urine leak and catheter 
obstruction, all efforts should be made 
to try to minimize the duration of 
catheterization and so reduce comorbidity 
and healthcare costs. 
  When the ﬁ  rst TWOC was successful, 
5.7% of patients had deferred surgery 
irrespective of the outcome whereas 
19.7% would undergo surgery only if 
needed. Although ﬁ  gures appear slightly 
higher for spontaneous AURs compared 
with precipitated AURs, these results show 
that a ﬁ  rst episode of AUR is not an 
absolute indication for surgery and that 
deferred surgery   ‘  if needed  ’   is the preferred 
option among urologists worldwide. In the 
second phase of the ALFAUR study, which 
randomized patients with successful TWOC 
to alfuzosin 10     mg once daily or placebo for 
6 months, BPH-related surgery was needed 
in 17.1% of patients treated with alfuzosin 
vs 24.1% of patients receiving placebo, 
mainly  because  of  AUR  relapse    [ 19 ]    .  A 
retrospective analysis of 165     527 men 
admitted for AUR between 1998 and 2003 
in NHS hospitals revealed that BPH-related 
surgery after a ﬁ  rst episode of AUR tended 
to decrease over time, being required in 
32% of men with spontaneous AUR and 
5.8% of men with precipitated AUR in 
2003    [ 13 ]  .  Conversely,  the  percentage  of 
patients readmitted for AUR relapse slightly 
increased over the same period. These data 
emphasize the need to evaluate carefully 
the risk of unfavourable outcome after 
TWOC to identify patients who may beneﬁ  t 
from a prolonged medical therapy without 
developing complications and those who 
need to undergo surgery in the short-term. 
In our survey, enlarged prostates, severe 
LUTS, large drained volume and AUR of 
spontaneous origin were associated with 
an increased risk of TWOC failure. These 
variables have also been identiﬁ  ed as 
predictors of recurrent AUR/surgery after 
a  successful  TWOC    [ 9,18,20 ]  .  They  could  be 
used to select patients who should rapidly 
be offered a surgical procedure. 
  In conclusion, this large cross-sectional 
survey, which enrolled 6074 men with BPH 
catheterized for AUR, evaluates prospectively 
the management of this urological 
emergency in a wide range of healthcare 
systems. It shows that urethral 
catheterization followed by a TWOC is the 
standard practice worldwide and that 
  α  1  -blockade before TWOC doubles the 
chances of success. Nevertheless, it also 
highlights important differences between 
countries regarding hospitalization rate, 
duration of catheterization and management 
of TWOC outcome, which are attributed to 
lack of guidelines for AUR management. 
Multivariate analysis of predictors of TWOC 
outcome reveal that catheterization for   > 3 
days does not inﬂ  uence the success rate but 
is associated with a greater comorbidity and 
prolonged hospitalization for adverse events. 
Older age, severe LUTS, large drained volume 
at catheterization and AUR of spontaneous 
origin favour TWOC failure. As these 
variables also predict the risk of recurrent 
AUR/surgery after a successful TWOC, they 
could be used to identify the subgroup of 
patients that cannot be managed by medical MANAGEMENT OF ACUTE URINARY RETENTION ASSOCIATED WITH BPH
©  2011 THE AUTHORS
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therapy alone and should rapidly undergo 
surgery.   
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